Peptide Insider

Cagrilintide Side Effects: What the Trials Actually Measured

Cagrilintide side effects — what the trials actually measured

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-02 · Last updated: 2026-09-16

Cagrilintide side effects are unusually well mapped for a research-market peptide, because this is one of the few compounds sold as a “research chemical” that has real, large, placebo-controlled human trials behind it — 706 people in the phase 2 dose-finding study and 3,417 in the CagriSema phase 3. The short answer: the side effects are mostly gastrointestinal, clearly dose-dependent, concentrated in the early escalation weeks, and mainly mild-to-moderate. This page gives you the actual rates, with citations, and flags exactly where the trial data stops applying to a research vial.

Quick Answer: The Most Common Cagrilintide Side Effects

In the phase 2 trial, gastrointestinal effects led everything: nausea in 20–47% of participants depending on dose (vs 18% on placebo), plus constipation and diarrhea, with GI events overall in 41–63% (vs 32% placebo). Injection-site reactions were the other frequent category. Most events were mild to moderate; 4% of participants across groups stopped treatment because of adverse events. Combined with semaglutide (CagriSema), GI events rise to 79.6%.

★The Documented Experience of 4,200+ Trial Participants

The most complete “user experience” of cagrilintide that exists belongs to the people who actually took it under observation. Across the phase 2 and phase 3 trials, the typical participant’s arc looked like this: appetite and fullness changes early, gastrointestinal effects — nausea most commonly — clustering around dose starts and each escalation step, then settling as exposure stabilized.

Most who experienced side effects rated them mild to moderate; the phase 3 investigators called them “mainly transient.” The clearest single fact about how tolerable participants found it: 96% of phase 2 participants did not stop treatment because of adverse events — and the placebo group reported nearly as many total adverse events as the treatment groups did.

What that experience came with: screening, monitoring, pharmaceutical-grade product, and clinician-managed dose escalation — none of which ships with a research vial.

Compiled from the published trials (PMID 34798060, PMID 40544433, PMID 33894838) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is Cagrilintide?

Cagrilintide is a long-acting analogue of amylin — the pancreatic hormone your body co-releases with insulin to signal fullness (PMID 34288673). Novo Nordisk engineered it for once-weekly injection and is developing it two ways: alone, and co-administered with semaglutide as CagriSema, the combination that produced 20.4% average weight loss in its phase 3 trial. It is not an approved drug anywhere as of this writing — everything sold under this name outside a trial is research-market material, a distinction that matters more on this page than on most.

How It Works — and Why the Side Effects Follow the Mechanism

Amylin analogues slow gastric emptying and act on brainstem satiety circuits — receptor-knockout work shows cagrilintide’s weight effect runs specifically through amylin receptors 1 and 3 in regions like the dorsal vagal complex (PMID 40609154). That mechanism is the side-effect profile: a compound built to make you feel full sooner produces, at higher exposures, the overshoot versions of fullness — nausea, early satiety, constipation. Understanding that makes the trial numbers below predictable rather than alarming.

KEY TAKEAWAY

Cagrilintide’s side effects are its mechanism turned up too far. That’s why they track dose so cleanly in the data — and why the trials managed them with slow dose escalation rather than any add-on fix.

The Trial Numbers That Matter

Three datasets do the heavy lifting on this page. The phase 2 dose-finding trial: 706 adults with overweight or obesity, randomized across cagrilintide 0.3–4.5mg weekly, liraglutide, and placebo for 26 weeks (PMID 34798060). The phase 1b combination trial: 96 adults on ascending cagrilintide doses plus semaglutide 2.4mg (PMID 33894838). And REDEFINE 1, the phase 3 CagriSema trial: 3,417 participants over 68 weeks (PMID 40544433). A separate phase 2 ran in type 2 diabetes (PMID 37364590). For a compound circulating on research sites, that is an exceptional evidence base — most peptides we cover would kill for one such trial.

Gastrointestinal Side Effects: The Real Rates

The phase 2 numbers, exactly as reported: gastrointestinal adverse events in 41–63% of cagrilintide participants versus 32% on placebo, led by nausea at 20–47% versus 18% on placebo, with constipation and diarrhea the other named contributors (PMID 34798060). Two readings of those ranges matter. First, the floor isn’t zero even on placebo — a third of placebo participants reported GI events, so the attributable share is smaller than the raw number. Second, the spread from 41% to 63% isn’t noise; it’s the dose axis, covered below.

PERSONAL OBSERVATION — PI EDITORIAL

Reading the three trials side by side, the number that changed how we read every other cagrilintide claim was the placebo column: 18% of placebo participants reported nausea, and 32% reported GI events, without a milligram of active drug. Most side-effect discussion online never subtracts that baseline. Once you do, the attributable effect is real but considerably smaller than the raw percentages suggest.

In REDEFINE 1’s combination arm, GI events reached 79.6% versus 39.9% on placebo — nausea, vomiting, diarrhea, constipation, and abdominal pain — but the authors’ characterization is worth quoting precisely: “mainly transient and mild-to-moderate in severity” (PMID 40544433). Serious outcomes were not the story of these trials; discontinuation was. In phase 2, 10% of participants permanently stopped treatment across all groups, 4% because of adverse events.

Injection-Site Reactions

The phase 2 trial names “administration-site reactions” as the other frequent adverse-event category alongside GI effects (PMID 34798060) — redness, irritation, or discomfort where the weekly subcutaneous dose goes in. The abstract doesn’t break out a percentage, so neither will we. Worth knowing for context: in the phase 1b trial, 97% of participants reported at least one adverse event of any kind — and so did 96% of the placebo group (PMID 33894838). In tightly monitored trials, nearly everyone reports something; the placebo column is what makes any number interpretable.

PRACTICAL NOTES — STANDARD SUBCUTANEOUS HANDLING

  • Reconstituted solutions brought to room temperature before use are standard practice in clinical settings
  • Site rotation (abdomen, thigh, upper arm) is how trial protocols manage repeated weekly injections
  • Sterile technique — clean site, single-use needles — is non-negotiable in any protocol, trial or lab
  • Our bacteriostatic water guide covers reconstitution handling in detail

Beyond the Gut: Metabolic and Cardiovascular Findings

The trial abstracts name gastrointestinal disorders and administration-site reactions as the frequent adverse-event categories — cardiovascular events do not appear among them. On the metabolic side, the findings ran favorable: the phase 1b reported that “glycaemic parameters improved in all treatment groups” (PMID 33894838), and a dedicated phase 2 tested the combination in people with type 2 diabetes (PMID 37364590). What we won’t do is convert “not reported as frequent” into “proven cardiovascular safety” — that claim belongs to dedicated outcome trials that haven’t been published. The honest summary: GI effects are the documented cost; metabolic markers moved in the beneficial direction; heart-level outcomes are simply not yet characterized.

When Side Effects Happen — and When They Fade

You’ll find month-by-month side-effect calendars for this compound online; the honest version is simpler and comes straight from trial design. GI effects cluster around dose starts and dose increases — which is why every trial escalated slowly — and the phase 3 authors describe events as “mainly transient” (PMID 40544433). Translated: the risky windows are the first weeks at any new exposure level, and most events resolve without intervention. What no published data supports is a precise “week 7 is the worst, week 10 you’re free” schedule — individual variation in the trials was wide, and anyone giving you an exact calendar made it up.

Long-Term Safety: What 68 Weeks Can and Can’t Tell You

The longest published exposure window is REDEFINE 1’s 68 weeks in 3,417 people (PMID 40544433) — sixteen months, with events characterized as mainly transient and mild-to-moderate. That’s meaningful reassurance for the first year-plus, and it is also the entire horizon: multi-year data doesn’t exist, because the compound isn’t old enough to have any. Anyone speaking about cagrilintide’s five-year profile is forecasting, not reporting.

Who the Trials Excluded

Trial safety numbers describe trial populations. The phase 2 enrolled adults with obesity, or overweight plus hypertension or dyslipidaemia — and excluded people with diabetes (PMID 34798060); the phase 1b enrolled 18–55-year-olds who were “otherwise healthy” (PMID 33894838). The rates on this page were generated in screened, monitored populations with clinicians adjusting doses — a context no research buyer replicates. That’s not a technicality; it’s the boundary of what these numbers can promise.

Managing and Minimizing Side Effects: What the Trials Did

The trials’ entire side-effect management strategy was structural: start low, escalate slowly, hold at each step — four-week intervals between dose increases in the phase 1b (PMID 33894838). No anti-nausea co-medication protocol appears in these abstracts; the escalation schedule was the management. We report that as trial design rather than advice, and note its logic: the dose-dependence data above is exactly why gradual exposure works. The other measurable lever is the one nobody markets — the 0.3mg group’s nausea rate (20%) was barely above placebo’s 18%. Lower exposure, fewer effects, less weight loss: the trade was linear.

Dose and Side Effects: The Correlation Is Measured

This is the rare peptide where the dose–side-effect curve was actually plotted in humans. Across the phase 2 dose groups from 0.3mg to 4.5mg weekly, nausea climbed from 20% to 47% — roughly, each step up the dose ladder bought more weight loss (6.0% up to 10.8%) and more GI effects. The trials also all used stepwise dose escalation — the phase 1b protocol raised doses only every four weeks (PMID 33894838) — which is a description of how the studies were run, not a protocol recommendation from us. The pattern it reflects: exposure the body has adapted to gradually is tolerated better than the same exposure arrived at quickly.

Two bar charts from the cagrilintide phase 2 trial: nausea 18% on placebo, 20% at 0.3 mg, 47% at 4.5 mg; any gastrointestinal adverse event 32% on placebo, 41% at 0.3 mg, 63% at 4.5 mg.
Chart: placebo versus the lowest and highest cagrilintide dose arms in the 26-week phase 2 trial, plotted from the published rates (PMID 34798060). The abstract reports the intermediate arms as ranges, so only the endpoints are plotted — and the placebo column is the part most write-ups leave out.

DID YOU KNOW

Cagrilintide’s half-life measured 159–195 hours — roughly a week (PMID 33894838). That’s the entire reason it’s a once-weekly compound, and it also means side effects can’t be “reset” quickly: a dose taken today is still substantially in circulation seven days later.

Cagrilintide Alone vs Stacked: What Combining Costs

The most-searched cagrilintide questions are about stacking it with GLP-1s, and here the data is unusually direct. Alone: GI events in 41–63%. With semaglutide 2.4mg: 79.6%. That’s the measured price of the combination that also roughly doubled the weight loss — both effects are real, and they arrive together. Note what this does and doesn’t cover: the trials tested cagrilintide with semaglutide. Pairings with retatrutide or tirzepatide — the exact stacks research forums discuss most — have no published human safety data at all. Whatever their logic, their side-effect profile is unmeasured, and the 79.6% figure cannot be borrowed for them. Our GLP-3 sourcing guide and retatrutide vendor page cover that family separately.

How Cagrilintide Compares to Other Weight-Loss Compounds

One comparison was run head-to-head: cagrilintide 4.5mg beat liraglutide 3.0mg on weight loss (10.8% vs 9.0%, p=0.03) in the phase 2 (PMID 34798060) — with GI-led side-effect profiles in the same family. Against semaglutide and tirzepatide there’s no standalone head-to-head; the comparison that exists is the combination arithmetic above. Amylin analogues as a class are being positioned as the gentler-nausea alternative to high-dose GLP-1s, but for cagrilintide specifically that’s a hypothesis the selective-amylin generation (eloralintide and peers) was designed to test — our eloralintide side effects breakdown picks that up. For the GLP-1 family itself, start with our retatrutide primer.

Where the Trial Data Stops: The Research-Vial Reality

Everything above describes pharmaceutical-grade cagrilintide, manufactured by Novo Nordisk, dosed under supervision. A lyophilized vial from a research-chemical storefront shares a molecule name with that product and nothing else that’s verifiable without testing. The gap shows up three ways: identity and purity (a batch-matched COA is the only evidence the vial contains dose-accurate cagrilintide), concentration arithmetic (reconstitution with bacteriostatic water is on the buyer — our peptide calculator handles the math and deliberately nothing else), and no medical monitoring, which is the invisible ingredient in every trial safety table. Compounds in this channel are sold strictly for non-human research use.

Sourcing and Verification

Cagrilintide is new enough to the research market that supply is uneven and quality claims run ahead of documentation. The checklist doesn’t change: batch-matched COA naming the compound and quantity, independent third-party testing with a verifiable report number, and skepticism toward any listing quoting trial statistics as if they applied to the vial. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews show what passing documentation looks like, and our guide library covers verification in depth. We don’t yet track live cagrilintide prices; when our tested vendors stock it, this section gets the live table.

US Regulatory Status

Cagrilintide is an investigational compound: not FDA-approved alone or as CagriSema as of this writing, with the combination in late-stage development. Practically, that means no prescription version exists to compare against, every vial in circulation is research-market material sold for non-human research use, and no regulator has evaluated any of those products for identity, purity, or the safety profile described above. When approval status changes, this section changes with it.

PERSONAL OBSERVATION — PI EDITORIAL

In our time reviewing research-market listings across this compound family, the pattern we see most is trial statistics quoted beside vials the trials never tested — a 20.4% weight-loss figure that belongs to pharmaceutical-grade CagriSema under medical supervision, sitting on a product page for an unverified lyophilized powder. No vial inherits a trial’s results. The COA is the only document that says anything about the one in your hand.

The rest of the amylin lineage now has its own breakdown: petrelintide side effects and amycretin side effects — and for the GLP-1 side of the stacking question, retatrutide side effects.

For vial-to-units arithmetic, our cagrilintide dosage calculator converts only what you enter and lists the trial doses as context.

Frequently Asked Questions

What are the most common cagrilintide side effects?

Gastrointestinal effects dominate: nausea (20–47% by dose vs 18% placebo), constipation, and diarrhea, plus injection-site reactions. In the phase 2 trial, GI adverse events affected 41–63% of cagrilintide participants versus 32% on placebo, mostly mild to moderate.

How long do cagrilintide side effects last?

Trial data ties GI effects to dose starts and increases — the arms, escalation schedules and per-dose rates are laid out in our cagrilintide dosage report — and the phase 3 authors describe them as “mainly transient and mild-to-moderate.” No published data supports an exact week-by-week schedule — the honest version is: hardest at each new dose level, easing with time at stable exposure.

Does a higher cagrilintide dose mean more side effects?

Yes, and it’s measured: across 0.3–4.5mg weekly, nausea rose from 20% to 47% while weight loss rose from 6.0% to 10.8%. Dose and side effects climbed together in the phase 2 trial.

Are cagrilintide’s side effects worse with semaglutide (CagriSema)?

The combination raised GI adverse events to 79.6% (vs 39.9% placebo) in the 3,417-person phase 3 — alongside 20.4% average weight loss. Both the benefit and the cost of stacking are real and documented.

Is cagrilintide safe?

In trials, most adverse events were mild to moderate, and only 4% of phase 2 participants stopped due to adverse events — in screened, monitored populations using pharmaceutical-grade product. No equivalent safety data exists for research-market vials, which is a different question the trials cannot answer.

What about cagrilintide with retatrutide or tirzepatide?

No published human trial has tested those combinations. The only stacked safety data that exists is cagrilintide plus semaglutide; every other pairing’s side-effect profile is unmeasured.

Glossary of Terms

  • Amylin: a pancreatic hormone co-released with insulin that signals fullness; cagrilintide is its long-acting analogue.
  • CagriSema: cagrilintide co-administered with semaglutide 2.4mg — the phase 3 combination.
  • Adverse event (AE): any unwanted medical occurrence during a trial, related to the drug or not; placebo groups report them too.
  • Dose escalation: the trial practice of raising doses stepwise (every 4 weeks in the phase 1b) so tolerance develops.
  • Half-life: time for blood levels to fall by half — 159–195 hours for cagrilintide, the basis of weekly dosing.
  • Discontinuation rate: the share of participants who stop treatment — often more informative than raw side-effect counts.
  • COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing.

References